Speech impairment as a marker of clinical changes in premanifest Huntington’s disease
Objective: Speech disturbances have been described in premanifest Huntington’s Disease (HD). Yet a recent systematic review and meta-analysis highlighted disagreement in the literature regarding the…Assessment of Gait in Huntington’s disease patients using EncephaLog smartphone’s application
Objective: Huntington’s disease (HD) patients cope with unique gait disturbances. Proper evaluation of gait in these patients is highly needed. Dyskinesia may negatively affect validity…Impact of caring for patients with Huntington’s disease on work status
Objective: To describe changes in the employment status of family members caring for a person with Huntington’s disease (HD) in the US and Europe. Background:…Involuntary movements with abnormal brain imaging: A Case Report
Objective: To present a case of juvenile-onset Huntington's disease (HD) with a mixed phenotype and abnormal brain imaging. Background: HD is an autosomal-dominant neurodegenerative disorder…Effects of Cognitively Challenging Agility Exercise Program on Clinical and Objective Measures in People with Parkinson’s Disease
Objective: To investigate the effects of a 6-week cognitively challenging exercise intervention in people with Parkinson’s disease (PD). Background: Gait and balance impairments have been…Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study
Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients
Objective: To assess safety, tolerability, and central effects of L-Dihydroxyphenylserine (L-DOPS), in Parkinson’s disease (PD) patients treated with DOPA decarboxylase inhibition. Background: Norepinephrine (NE) is…Development Of Anti-Parkinsonism Poly Herbal Sustained Release Formulation Composed Of Potential Traditional Plant Extracts
Objective: Parkinsonism is one of the commonest neurodegenerative diseases, which is characterized by a selective and progressive degeneration of dopaminergic neurons, causing a series of…Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom
Objective: To investigate whether the use of Opicapone as an add-on therapy to levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD) reduces the…Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions
Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 217
- Next Page »